MA55017A - Procédés de marquage de cellules eucaryotes à partir d'un organisme multicellulaire ainsi que pour le traitement et/ou le diagnostic d'un cancer à l'aide de composés monosaccharidiques modifiés - Google Patents

Procédés de marquage de cellules eucaryotes à partir d'un organisme multicellulaire ainsi que pour le traitement et/ou le diagnostic d'un cancer à l'aide de composés monosaccharidiques modifiés

Info

Publication number
MA55017A
MA55017A MA055017A MA55017A MA55017A MA 55017 A MA55017 A MA 55017A MA 055017 A MA055017 A MA 055017A MA 55017 A MA55017 A MA 55017A MA 55017 A MA55017 A MA 55017A
Authority
MA
Morocco
Prior art keywords
monosaccharidic
eukaryot
labeling
diagnosis
cancer
Prior art date
Application number
MA055017A
Other languages
English (en)
Inventor
Sam Dukan
Original Assignee
Diamidex
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Diamidex filed Critical Diamidex
Publication of MA55017A publication Critical patent/MA55017A/fr

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G01N33/57488Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds identifable in body fluids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00Preparations for testing in vivo
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/531Production of immunochemical test materials
    • G01N33/532Production of labelled immunochemicals
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/58Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/84Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving inorganic compounds or pH
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H3/00Compounds containing only hydrogen atoms and saccharide radicals having only carbon, hydrogen, and oxygen atoms
    • C07H3/02Monosaccharides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Inorganic Chemistry (AREA)
  • Epidemiology (AREA)
  • Public Health (AREA)
  • Genetics & Genomics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
MA055017A 2019-02-20 2020-02-20 Procédés de marquage de cellules eucaryotes à partir d'un organisme multicellulaire ainsi que pour le traitement et/ou le diagnostic d'un cancer à l'aide de composés monosaccharidiques modifiés MA55017A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP19305202 2019-02-20

Publications (1)

Publication Number Publication Date
MA55017A true MA55017A (fr) 2021-12-29

Family

ID=65766918

Family Applications (1)

Application Number Title Priority Date Filing Date
MA055017A MA55017A (fr) 2019-02-20 2020-02-20 Procédés de marquage de cellules eucaryotes à partir d'un organisme multicellulaire ainsi que pour le traitement et/ou le diagnostic d'un cancer à l'aide de composés monosaccharidiques modifiés

Country Status (15)

Country Link
US (1) US20220146516A1 (fr)
EP (1) EP3928097A1 (fr)
JP (1) JP2022521528A (fr)
KR (1) KR20210132097A (fr)
CN (1) CN113677997A (fr)
AU (1) AU2020225034A1 (fr)
BR (1) BR112021016399A2 (fr)
CA (1) CA3129125A1 (fr)
EA (1) EA202192289A1 (fr)
IL (1) IL284854A (fr)
MA (1) MA55017A (fr)
MX (1) MX2021009987A (fr)
SG (1) SG11202108422XA (fr)
WO (1) WO2020169782A1 (fr)
ZA (1) ZA202106893B (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4200613A1 (fr) * 2020-08-19 2023-06-28 Theraonco Composé monosaccharidique pour le marquage de la sécrétion cellulaire
US20240027435A1 (en) * 2020-08-19 2024-01-25 Theraonco Method and kit for labeling eukaryotic cells from a multicellular organism using modified monosaccharide compounds and pharmaceutical composition comprising such cells

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050004044A1 (en) * 2003-04-07 2005-01-06 Board Of Regents Use of orsaponin [3beta, 16beta, 17 alpha-trihydroxycholost-5-en-22-one 16-0-(2-0-4-methoxybenzoyl-beta-D-xylopyranosyl)-(1->3)-(2-0-acetyl-alpha-L-arabinopyranoside)] or OSW-1 and its derivatives for cancer therapeutics
EP2623610B1 (fr) * 2006-02-10 2015-04-29 Life Technologies Corporation Marquage et détection de protéines modifiées post-traductionnellement
JP6059533B2 (ja) * 2009-11-09 2017-01-11 ユニバーシティ オブ ワシントン センター フォー コマーシャライゼーション 官能化発色性ポリマードットおよびその生物共役体
US9809560B2 (en) * 2010-08-09 2017-11-07 Albert Einstein College Of Medicine, Inc. Ligands and methods for labeling biomolecules in vivo
KR101159172B1 (ko) 2011-11-24 2012-08-07 학 성 김 Id카드이용 선후불겸용결제 방법 및 시스템
EP2617833A1 (fr) 2012-01-18 2013-07-24 Centre National de la Recherche Scientifique (CNRS) Procédé de détection spécifique de bactéries vivantes
EP3091081A1 (fr) 2015-05-04 2016-11-09 Centre National de la Recherche Scientifique (CNRS) Procédé pour marquer spécifiquement des bactéries vivantes comprenant l'utilisation de composés de monosaccharide modifiés
KR20180058737A (ko) * 2015-10-07 2018-06-01 더 보오드 오브 트러스티스 오브 더 유니버시티 오브 일리노이즈 암 선택적 표지화 및 표적화를 위한 트리거-활성화 대사성 당 전구체
EP3170830A1 (fr) * 2015-11-17 2017-05-24 Centre National De La Recherche Scientifique Nouveaux composés de 5-azido-5-deoxy-2 : 3-isopropylidene-d-arabinose ; leur procédé de fabrication et leur utilisation pour la synthèse de ara-n3, kdo-n3 et 4ekdo-n3

Also Published As

Publication number Publication date
CN113677997A (zh) 2021-11-19
KR20210132097A (ko) 2021-11-03
CA3129125A1 (fr) 2020-08-27
US20220146516A1 (en) 2022-05-12
EP3928097A1 (fr) 2021-12-29
ZA202106893B (en) 2023-06-28
IL284854A (en) 2021-08-31
AU2020225034A1 (en) 2021-08-19
EA202192289A1 (ru) 2021-11-17
JP2022521528A (ja) 2022-04-08
WO2020169782A1 (fr) 2020-08-27
SG11202108422XA (en) 2021-09-29
MX2021009987A (es) 2021-11-04
BR112021016399A2 (pt) 2021-10-19

Similar Documents

Publication Publication Date Title
MA55017A (fr) Procédés de marquage de cellules eucaryotes à partir d'un organisme multicellulaire ainsi que pour le traitement et/ou le diagnostic d'un cancer à l'aide de composés monosaccharidiques modifiés
MA52494A (fr) Formes solides d'un inhibiteur de fgfr et leurs procédés de préparation
MA53096A (fr) Composés et compositions destinés au traitement d'états pathologiques associés à une activité de sting
MA33662B1 (fr) Composés de spiropipéridine et leur utilisation pharmaceutique pour le traitement du diabète
MA34234B1 (fr) Composes pyrazol-4-yl-heterocyclyle-carboxamide et leurs procedes d'utilisation
BR112015008255A2 (pt) método para o diagnóstico, prognóstico e tratamento de metástase de câncer de próstata
BR112014031414A2 (pt) métodos de detectar doenças ou condições utilizando células doentes circulantes
MA41203B1 (fr) Procédés pour la préparation d'un composé diaryl-thiohydantoïne
MA55917A (fr) Procédé de cristallisation de dérivés d'aripiprazole dans des formulations à libération prolongée pour le traitement de la schizophrénie
MA55148A (fr) Composés d'aryl-aniline et d'hétéroaryl-aniline pour le traitement de marques de naissance
MA47381A (fr) Procédés et micro-organismes de fabrication de 2,3-butanediol et ses dérivés à partir de composés carbonés en c1
MA52137A (fr) Méthodes de traitement de l'amylose ttr à l'aide d'ag10
MA38307A1 (fr) 4-hydroxy-2-méthyl-5-(propan-2-ylidène)cyclohex-3-ènecarbaldéhyde pour la prévention et le traitement d'une maladie cognitive, neurodégénérative ou neuronale
MA54741A (fr) Composés thiényl-aniline destinés au traitement d'affections de la peau
Spindler The basal Sphenacodontia–systematic revision and evolutionary implications
FR2923479B1 (fr) Installation pour le traitement d'eaux residuaires et disque biologique pour une telle installation
MA34291B1 (fr) Compositions et méthodes de diagnostic et de traitement d'une tumeur
MA56186A (fr) Composés pour le traitement d'une maladie respiratoire
FR2904004B1 (fr) Modulateurs de scarb-1 dans le traitement de l'acne ou de l'hyperseborrhee
MA55595A (fr) Composés pour le traitement du cancer induit par un oncovirus et leurs procédés d'utilisation
FR2917172B1 (fr) Methode de mesure de l'activite plasmine des microparticules presentes dans un echantillon de fluide biologique et utilisation
FR3017536B1 (fr) Compositions pour la prevention et/ou le traitement de pathologies liees a l'alpha-glucosidase
MA43977A (fr) Méthode de traitement de patients atteints de cancer souffrant d'insuffisance rénale grave
MA43732A (fr) Procédé de diagnostic d'un cancer pouvant être traité par un promédicament étoposide
Wenzel Cognitive restructuring: Automatic thoughts.